11:24 AM EDT, 05/28/2024 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Tuesday that the phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism, also known as Cushing's syndrome, met its primary endpoint of loss of blood pressure control in the second, randomized withdrawal phase.

The company said the trial has two phases and patients who demonstrated pre-specified improvements in hypertension, hyperglycemia or both after the initial open-label phase were allowed to proceed to the second, double-blind withdrawal phase.

Corcept said relacorilant was well-tolerated in both phases of the trial, consistent with its known safety profile, and additional data will be presented at an upcoming medical meeting. The company also said it expects to submit a new drug application for relacorilant in Q3.

Shares of Corcept Therapeutics ( CORT ) were up more than 14% in recent trading.

Price: 31.48, Change: +3.96, Percent Change: +14.39